Abstracts tagged "Comorbidity"

Abstract Number: 1631 • ACR Convergence 2023
Comparison of Peripheral Biomarker Profiles Across Unique Multimorbidity Patterns in Rheumatoid Arthritis
Chloe Peyton¹, Tate Johnson¹, Joshua Baker², Yangyuna Yang¹, Punyasha Roul¹, Michael Duryee¹, Jill Poole¹, Geoffrey Thiele¹, Ted R Mikuls³ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA) predisposes affected individuals to develop multiple chronic conditions (i.e., multimorbidity). Mechanisms underlying multimorbidity onset in RA are incompletely understood, particularly for…
Abstract Number: 0739 • ACR Convergence 2023
Major Adverse Cardiovascular Event and Venous Thromboembolism Risk Comparing Advanced Therapies Among Individuals with Axial Spondylarthritis and Psoriatic Arthritis
Sali Merjanah¹, Devin Driscoll², Christine Peloquin³, Jean liew³ and Maureen Dubreuil⁴, ¹Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ²Boston University/Boston Medical Center, Boston, MA, ³Boston University, Boston, MA, ⁴Department of Rheumatology, Boston University School of Medicine, Milton, MA
Background/Purpose: Individuals with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) have increased cardiovascular risk compared to the general population, which is partly explained by systemic…
Abstract Number: 1632 • ACR Convergence 2023
Incident Malignancies in Patients with Rheumatoid Arthritis in Daily Rheumatological Care
Martin Schaefer¹, Yvette Meissner¹, Bernhard Manger², Sylvia Berger³, Karin Rockwitz⁴, Anne Regierer⁵ and Anja Strangfeld¹, ¹German Rheumatism Research Center, Berlin, Germany, ²Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³Rheumatologist, Naunhof, Germany, ⁴Rheumatologist, Goslar, Germany, ⁵Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany
Background/Purpose: In 2021, the European and US-American regulatory agencies EMA and FDA issued warnings about malignancy risk associated with the Janus kinase inhibitor (JAKi) tofacitinib…
Abstract Number: 0869 • ACR Convergence 2023
Clinical Impact of PTEN as a Marker for Diabetes-Associated Osteoarthritis
Irene Lorenzo Gomez¹, Uxía nogueira Recalde², Christian García Domínguez¹, Natividad Oreiro Villar³, Jose Antonio Pinto Tasende³, Mohit Kapoor⁴, Francisco J. Blanco³ and Beatriz Carames¹, ¹Unidad de Biología del Cartílago, Grupo de Reumatología, Instituto de Investigación Biomédica de A Coruña (iNIBIC), A Coruña, Spain, ²Unidad de Biología del Cartílago, Grupo de Reumatología, Instituto de Investigación Biomedica de A Coruña (iNIBIC), A Coruña, Spain, ³Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ⁴Division of Orthopaedics, Osteoarthritis Research Program, Schroeder Arthritis Institute, and Krembil Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Defects in homeostatic mechanisms, such as autophagy, contribute to joint aging and Osteoarthritis (OA) and precede joint damage (1). OA is a complex and…
Abstract Number: 1855 • ACR Convergence 2023
Using a Whole-population Approach to Help Design More Effective and Efficient Healthcare Services for People with Fibromyalgia
Gary Macfarlane¹, Roxanne Cooksey², Ernest Choy³ and Rosemary Hollick⁴, ¹Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ²Cardiff University, Cardiff, United Kingdom, ³Section of Rheumatology, Cardiff University, Cardiff, United Kingdom, ⁴University of Aberdeen, Aberdeen, United Kingdom
Background/Purpose: A large body of evidence has informed, internationally, management recommendations for people with fibromyalgia. However there are very few studies which have examined how…
Abstract Number: 0985 • ACR Convergence 2023
Assessing the Value of Comorbidity Clusters in Predicting Clinical Outcomes in Rheumatoid Arthritis: A Machine Learning Approach Using a Very Large US Registry
Daniel Solomon¹, Fredrik Johansson², Hongshu Guan³, Leah Santacroce⁴, Lin Guo⁵, Wendi Malley⁵ and Heather Litman⁵, ¹Brigham and Women's Hospital, Newton, MA, ²Chalmers University of Technology, Goteborg, Sweden, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵CorEvitas, LLC, Waltham, MA
Background/Purpose: Comorbid conditions are very common in rheumatoid arthritis (RA) and several prior studies have derived comorbidity clusters using machine learning (ML). Clustering using ML…
Abstract Number: 1923 • ACR Convergence 2023
Prevalence and Patterns of Comorbidities in Different Rheumatic Diseases: A Study from Tertiary Healthcare Centre
Smruti Ramteke¹, sanjay Ramteke² and Sandeep Yadav³, ¹Arthritis Clinic, Jasleen Hospital, Nagpur, India, ²Government Super Speciality Hospital Nagpur, Nagpur, India, ³P D Hinduja national Hospital and medical Research centre, Mumbai, India
Background/Purpose: The prevalence of comorbidities in rheumatic diseases may vary by disease and geographic region. This study aimed to investigate the comorbidities associated with rheumatoid…
Abstract Number: 1078 • ACR Convergence 2023
Outcomes of COVID-19 Infection in Hospitalized Autoimmune Patients and Transplant Patients on Immunosuppression
Yashswee KC¹ and Rochella Ostrowski², ¹Loyola University, Oakpark, IL, ²Loyola University Medical Center, Maywood, IL
Background/Purpose: Coronavirus disease 2019 (COVID-19) can have varying outcomes. Patients with chronic conditions or immunosuppression experience more severe illness. Both organ transplant recipients and patients…
Abstract Number: 1966 • ACR Convergence 2023
Investigating Esophageal Involvement in Anti-Synthetase Syndrome: How to Discover the Submerged?
Federico Fattorini¹, Chiara Cardelli¹, Simone Barsotti², Michele Diomedi¹, Elenia Laurino¹, Mariano Grosso³, Linda Carli¹ and Marta Mosca¹, ¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ²Internal Medicine, Ospedale di Livorno, Pisa, Italy, ³Nuclear Medicine, Department of Translational Research and New Technology in Medicine, University of Pisa, Pisa, Italy
Background/Purpose: Anti-synthetase syndrome (ASS) is an idiopathic inflammatory myopathy, typically characterized from the triad interstitial lung disease (ILD), myositis and arthritis, together with anti-aminoacyl tRNA…
Abstract Number: 1212 • ACR Convergence 2023
Racial Disparities in Comorbidities and Perception of Physical Health in Systemic Lupus Erythematosus
OKEOGHENE AKPOIGBE¹, YONG EUN², COMFORT ANIM-KORANTENG² and AMANDA SAMMUT², ¹NYCHH- HARLEM, Bronx, NY, ²NYCHH- HARLEM, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multisystemic immune-mediated disease with often nonspecific symptoms, associated with recurrent flares that can be life threatening. Prevalence…
Abstract Number: 1969 • ACR Convergence 2023
Multimorbidity and PROMIS Health Outcomes in Patients with Idiopathic Inflammatory Myopathies: Analysis from the COVAD Study
Marco Fornaro¹, Vincenzo Venerito², Florenzo Iannone³, Naveen R⁴, Elena Nikiphorou⁵, Mrudula Joshi⁶, Ai Lyn Tan⁷, Sreoshy Saha⁸, Samuel Shinjo⁹, Vishwesh Agarwal¹⁰, Nelly Ziade¹¹, Tsvetelina Velikova¹², Esha Kadam¹³, Marcin Milchert¹⁴, Ioannis Parodis¹⁵, Abraham Edgar Gracia-Ramos¹⁶, Lorenzo Cavagna¹⁷, Masataka Kuwana¹⁸, Johannes Knitza¹⁹, Ashima Makol²⁰, Dey Dzifa²¹, CARLOS ENRIQUE TORO GUTIERREZ²², CARLO VINICIO CABALLERO²³, Oliver Distler²⁴, Jessica Day²⁵, Hector Chinoy²⁶, Vikas Agarwal⁴, Rohit Aggarwal²⁷, Latika Gupta²⁸ and COVAD Study Group²⁹, ¹University of Bari, Grottaglie, Italy, ²Rheumatology Department, Università degli Studi di Bari, Bari, Italy, ³Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ⁵King's College London, London, United Kingdom, ⁶Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India, ⁷University of Leeds, Leeds, United Kingdom, ⁸Mymensingh Medical College, Faridpur, Bangladesh, ⁹Faculdade de Medicina FMUSP, Universidade de Sao Paulo, São Paulo, Brazil, ¹⁰Mahatma Gandhi Missions Medical College, Lucknow, India, ¹¹Saint-Joseph University, Beirut, Lebanon, ¹²Department of Clinical Immunology, Medical Faculty, University Hospital "Lozenetz", Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ¹³Seth Gordhandhas Sunderdas Medical College and King Edwards Memorial Hospital, Mumbai, India, ¹⁴Department of Internal Medicine, Rheumatology, Diabetology, Geriatrics and Clinical Immunology, Pomeranian Medical University in Szczecin, Szczecin, Poland, ¹⁵Karolinska Institutet, Stockholm, Sweden, ¹⁶Department of Internal Medicine, General Hospital, National Medical Center "La Raza", Instituto Mexicano del Seguro Social, Av. Jacaranda S/N, Col. La Raza, Del. Azcapotzalco, C.P. 02990, Mexico City, Mexico, ¹⁷Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ¹⁸Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ¹⁹Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ²⁰Mayo Clinic, Rochester, MN, Rochester, MN, ²¹Department of Medicine and Therapeutics, University of Ghana School of Medicine and Dentistry, College of Health Sciences, Korle-Bu, Accra, Ghana, ²²Centro de Estudios de Reumatología y Dermatología SAS, Cali, Colombia, ²³REUMACARIBE IPS, Barranquilla, Colombia, ²⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²⁵Walter and Eliza Hall Institute, Melbourne, Australia, ²⁶The University of Manchester, Sale, United Kingdom, ²⁷University of Pittsburgh, Pittsburgh, PA, ²⁸Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom, ²⁹-, -
Background/Purpose: Comorbidities have a profound impact on the quality of life (QoL), though global data on the burden of comorbidities and its impact on health…
Abstract Number: 1276 • ACR Convergence 2023
Multimorbidity Burden Predicts Lower Likelihood of Remission in Patients with Rheumatoid Arthritis
Cynthia Crowson, Chanakya Kodishala, Tina Gunderson, Atkinson Elizabeth, Vanessa Kronzer, John Davis, Courtney Arment, Delamo Bekele, Thomas Mason, Lynne Peterson, Kerry Wright and Elena Myasoedova, Mayo Clinic, Rochester, MN
Background/Purpose: Seropositivity has historically been associated with poor disease outcomes in patients with rheumatoid arthritis (RA). Seronegative RA is on the rise and is associated…
Abstract Number: 2029 • ACR Convergence 2023
Health-Related Quality of Life in Idiopathic Inflammatory Myopathies: How to Act for Improving the Disease Burden of Patients?
Chiara Cardelli¹, Simone Barsotti², Elenia Laurino¹, Michele Diomedi¹, Federico Fattorini¹, Dina Zucchi³, Alessandra Tripoli¹, Linda Carli¹ and Marta Mosca¹, ¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ²Internal Medicine, Ospedale di Livorno, Pisa, Italy, ³Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy; Department of Medical Biotechnologies, University of Siena, Pisa, Italy
Background/Purpose: Idiopathic Inflammatory Myopathies (IIM) are rare, multisystemic and complex diseases that strongly impact the Quality of Life (QoL) of those affected. Patient Reported Outcomes…
Abstract Number: 1278 • ACR Convergence 2023
Nature and Severity of Activity Limitations According to the Health Assessment Questionnaire Disability Index in Patients with Rheumatoid Arthritis and Functional Disability
Manja van Wissen¹, Maaike gademan¹, Cornelia van den Ende², Max Teuwen¹, Wilfred Peter¹, Dirkjan van Schaardenburg³, Alfons den Broeder², Thea Vliet Vlieland⁴ and Salima van Weely¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Sint Maartenskliniek, Nijmegen, Netherlands, ³Reade, Amsterdam, Netherlands, ⁴Leids University Medical Center, Leiden, Netherlands
Background/Purpose: Not withstanding modern treatment, some Rheumatoid Arthritis (RA) patients have severe disability due to persistently high disease activity, joint destruction/deformities and/or comorbidities. Insight into…
Abstract Number: 2091 • ACR Convergence 2023
Reach and Representativeness of Participants in an Evidence-Based, Community-Delivered Physical Activity Intervention in Adults with Arthritis
Dina Jones¹ and Jennifer Hootman², ¹West Virginia University, Morgantown, WV, ²Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: It is imperative that adults with arthritis and other chronic conditions are active enough to maintain health. Enhance®Fitness (EF) is an evidence-based physical activity…

« Previous Page
1
…
6
7
8
9
10
…
22
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].